High Acquisition Premiums And Many Layoffs: Predictable Consequences Of Externalizing Pharma R&D

Rather than lament the R&D layoffs, and cheer the hefty acquisition price enjoyed by successful startups and small companies, we need to see these as integrated phenomenon.